PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 199 filers reported holding PDL BIOPHARMA INC in Q3 2016. The put-call ratio across all filers is 1.13 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $1,015,000 | +7.3% | 345,406 | 0.0% | 0.01% | +11.1% |
| Q4 2017 | $946,000 | -19.2% | 345,406 | 0.0% | 0.01% | -18.2% |
| Q3 2017 | $1,171,000 | +37.3% | 345,406 | 0.0% | 0.01% | +37.5% |
| Q2 2017 | $853,000 | +96.5% | 345,406 | +68.6% | 0.01% | +100.0% |
| Q4 2016 | $434,000 | -36.7% | 204,916 | 0.0% | 0.00% | -33.3% |
| Q3 2016 | $686,000 | +65.7% | 204,916 | +218.1% | 0.01% | +50.0% |
| Q2 2015 | $414,000 | -10.0% | 64,414 | -1.5% | 0.00% | 0.0% |
| Q1 2015 | $460,000 | -71.4% | 65,391 | -68.7% | 0.00% | -71.4% |
| Q4 2014 | $1,610,000 | +2.0% | 208,901 | -1.2% | 0.01% | -26.3% |
| Q3 2014 | $1,579,000 | +19.2% | 211,352 | +32.5% | 0.02% | +72.7% |
| Q1 2014 | $1,325,000 | +326.0% | 159,473 | +333.4% | 0.01% | +266.7% |
| Q4 2013 | $311,000 | -1.6% | 36,798 | -10.2% | 0.00% | -25.0% |
| Q2 2013 | $316,000 | – | 40,986 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 2,632,000 | $8,817,000 | 2.83% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 551,804 | $1,848,543,000 | 1.54% |
| Nine Chapters Capital Management LLC | 24,300 | $81,000 | 0.57% |
| GREAT POINT PARTNERS LLC | 645,000 | $2,161,000 | 0.55% |
| Virtus ETF Advisers LLC | 198,901 | $666,000 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 1,521,224 | $5,096,000 | 0.27% |
| Amici Capital, LLC | 200,000 | $670,000 | 0.18% |
| Acrospire Investment Management LLC | 70,622 | $237,000 | 0.16% |
| RBF Capital, LLC | 273,976 | $918,000 | 0.16% |
| SECOR Capital Advisors, LP | 383,971 | $1,286,000 | 0.14% |